Piramal Critical Care collaborates with Blue-Zone to launch innovative waste anaesthetic gas recycling initiative.
Piramal Critical Care, a leading provider of inhalation anaesthetics, has partnered with Blue-Zone Technologies, a pioneer in anaesthetic gas recycling, to launch a groundbreaking initiative aimed at reducing the environmental impact of waste anaesthetic gases. This innovative collaboration seeks to address the significant problem of anaesthetic gas waste, which contributes to greenhouse gas emissions and poses a threat to the environment.
The partnership involves the deployment of Blue-Zone’s patented anaesthetic gas recycling technology, which captures and recycles waste anaesthetic gases, thereby reducing the amount of these potent greenhouse gases released into the atmosphere. This technology has the potential to significantly decrease the carbon footprint of healthcare facilities and contribute to a more sustainable future.
Under the terms of the agreement, Piramal Critical Care will work closely with Blue-Zone to promote and implement the anaesthetic gas recycling technology in healthcare facilities across the United States and Europe. The company will leverage its extensive network and expertise in the field of inhalation anaesthetics to raise awareness about the importance of anaesthetic gas recycling and the benefits of this innovative technology.
The recycling process involves the use of a specialized device that captures the waste anaesthetic gases and recycles them, resulting in a significant reduction in greenhouse gas emissions. This technology has been shown to be highly effective, with the ability to capture up to 90% of waste anaesthetic gases. By reducing the amount of these gases released into the atmosphere, healthcare facilities can significantly decrease their environmental impact and contribute to a more sustainable future.
The partnership between Piramal Critical Care and Blue-Zone Technologies is a significant step towards reducing the environmental impact of anaesthetic gas waste. The collaboration demonstrates the commitment of both companies to sustainability and their dedication to providing innovative solutions that prioritize the well-being of both patients and the environment. As the healthcare industry continues to evolve, partnerships like this one will play a crucial role in shaping a more sustainable future for generations to come. With the potential to significantly reduce greenhouse gas emissions, this initiative has the potential to make a substantial impact on the environment and public health.
Glenmark Pharmaceuticals sets sights on FY28 for debut of oncology drugs and expansion of profit margins, reports ETPharma.
Glenmark Pharmaceuticals, a leading Indian pharmaceutical company, has expressed confidence that its cancer drug, Trastuzumab Rezetecan (SHR-A1811), will enter licensed markets by FY28, driving an improvement in both gross and EBITDA margins. The company has guided for an EBITDA margin of 23% for the ongoing fiscal year and expects its higher-margin oncology assets to lift profitability. Trastuzumab Rezetecan, a HER2-targeted ADC, was in-licensed from China’s Hengrui Pharma in September 2025 for an upfront payment of $18 million and milestone payments of up to $1.093 billion.
Glenmark’s Chairman and MD, Glenn Saldanha, stated that the company’s oncology assets, including Trastuzumab Rezetecan and aumolertinib, will bring meaningful gains from FY28, driving long-term growth for the company. The company has also obtained exclusive rights for select markets, including India, and is exploring the treatment of HER2-positive cancers, such as non-small cell lung cancer (NSCLC) and breast cancer.
In addition to oncology, Glenmark’s leading respiratory asset, Ryaltris, is on track to become a $100 million brand on a moving annual basis. The company is also progressing well with its $1.9 billion out-licensing deal with AbbVie for the cancer asset ISB 2001, with Phase II trials expected to begin by the end of the current calendar year.
Glenmark has a net cash position of around Rs 600 crore and has reiterated its target to reduce gross debt to zero by March 2026. The company’s innovation spin-off, IGI, has an annual cash burn of $70 million. Commenting on the Union Budget 2026-27 announcement of Biopharma SHAKTI, a scheme to boost capacity creation for biologics and biosimilars, Saldanha said it is a positive development for the industry, although Glenmark does not currently have in-house manufacturing for biologics.
Overall, Glenmark is poised for growth driven by its oncology assets, and the company is confident that its strategic decisions will yield meaningful gains from FY28. With a strong focus on innovation and a robust pipeline of products, Glenmark is well-positioned to drive long-term growth and expansion in the pharmaceutical industry. The company’s commitment to reducing debt and increasing profitability is also expected to yield positive results, making it an attractive player in the Indian pharmaceutical sector.
HOSMAC has designed Cipla’s Breathefree Lung Wellness Centre in Mumbai, focusing on adaptive reuse and a wellness-centric approach, as reported by Prop News Time.
HOSMAC, a renowned healthcare design and consulting firm, has successfully designed Cipla’s Breathefree Lung Wellness Centre in Mumbai. The centre is a testament to HOSMAC’s expertise in creating healthcare facilities that prioritize patient-centric care and wellness. The design of the centre emphasizes adaptive reuse, transforming an existing building into a state-of-the-art lung wellness centre.
The Breathefree Lung Wellness Centre is a 5,000-square-foot facility located in the heart of Mumbai. The centre offers a comprehensive range of services, including lung function testing, pulmonary rehabilitation, and patient education. The design of the centre is centered around the concept of “wellness-led care,” which focuses on promoting overall well-being and preventive care rather than just treating illnesses.
HOSMAC’s design team worked closely with Cipla to create a space that is both functional and aesthetically appealing. The centre features a modern and sleek design, with ample natural light and ventilation. The interior design elements, including the color scheme and furniture, are carefully selected to create a calming and soothing atmosphere, conducive to patient recovery and wellness.
One of the key highlights of the centre is its emphasis on adaptive reuse. The existing building was transformed into a lung wellness centre, minimizing waste and reducing the environmental impact of the project. The design team worked closely with the existing structure, incorporating sustainable design principles and materials to create a energy-efficient and eco-friendly facility.
The Breathefree Lung Wellness Centre is equipped with cutting-edge technology and medical equipment, ensuring that patients receive the best possible care. The centre also features a team of experienced healthcare professionals, including pulmonologists, physiotherapists, and nutritionists, who work together to provide comprehensive care to patients.
The centre’s design and services are tailored to meet the specific needs of patients with lung diseases, such as chronic obstructive pulmonary disease (COPD) and asthma. The centre offers a range of programs and services, including pulmonary rehabilitation, smoking cessation, and patient education, to help patients manage their condition and improve their overall quality of life.
Overall, the Breathefree Lung Wellness Centre is a shining example of HOSMAC’s expertise in designing healthcare facilities that prioritize patient-centric care and wellness. The centre’s emphasis on adaptive reuse, wellness-led care, and sustainable design principles makes it a unique and innovative healthcare facility in Mumbai. With its state-of-the-art technology, experienced healthcare professionals, and comprehensive range of services, the centre is poised to become a leading destination for lung wellness and care in the region.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.